Simplify Asset Management Inc. Sells 44,496 Shares of Abivax SA Sponsored ADR $ABVX

Simplify Asset Management Inc. trimmed its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 72.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,953 shares of the company’s stock after selling 44,496 shares during the period. Simplify Asset Management Inc.’s holdings in Abivax were worth $2,286,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ABVX. UBS Group AG raised its stake in shares of Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after buying an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of Abivax during the third quarter worth approximately $263,698,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Abivax during the third quarter worth approximately $132,800,000. TCG Crossover Management LLC raised its stake in shares of Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after buying an additional 1,055,000 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Abivax during the third quarter worth approximately $84,900,000. 47.91% of the stock is owned by institutional investors.

Abivax Price Performance

Shares of ABVX stock opened at $121.99 on Monday. The firm has a fifty day moving average of $117.74 and a 200-day moving average of $119.12. Abivax SA Sponsored ADR has a 12-month low of $5.59 and a 12-month high of $148.83. The company has a market capitalization of $9.72 billion, a price-to-earnings ratio of -23.41 and a beta of 0.84.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts expect that Abivax SA Sponsored ADR will post -3.84 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on ABVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. BTIG Research reaffirmed a “buy” rating and issued a $150.00 target price on shares of Abivax in a research note on Wednesday, February 25th. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Jefferies Financial Group began coverage on shares of Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 target price for the company. Finally, Barclays upped their target price on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Abivax presently has an average rating of “Moderate Buy” and an average price target of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.